BioSpace News Archive

Biotech Bay

Mispro to Expand Contract Vivarium Network to Palo Alto

Innovative contract vivarium organization, Mispro, plans to expand its vivarium research labs network to Palo Alto’s prestigious Stanford Research Park.

May 18, 2023
·
2 min read
BioForest

Ozette Announces New Suite of Machine Learning-Powered Computational Analysis Solutions Coupled with High Dimensional Full Spectrum Cytometry Data Generation to Accelerate Decision-Making for Clinical Biomarker Teams

Ozette Endpoints™ delivers the fastest path from cytometry data to actionable results enabling clinical development teams to answer key biomarker questions to support pharmacodynamics, safety, and disease biology objectives.

May 18, 2023
·
5 min read
Biotech Bay

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

Pulse Biosciences, Inc. today announced nsPFA will be featured in three presentations at the upcoming Heart Rhythm 2023 Annual Meeting in New Orleans, LA from May 19-21.

May 18, 2023
·
2 min read
Drug Development

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Gossamer Bio, Inc. today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24.

May 18, 2023
·
4 min read
Pharm Country

Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic CancerRucosopasem in clinical development to augment the anti-cancer efficacy of stereotactic body radiation therapy

Galera Therapeutics, Inc. (Nasdaq: GRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Galera’s second product candidate, rucosopasem manganese (rucosopasem), for the treatment of pancreatic cancer.

May 18, 2023
·
6 min read
Business

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2023 and provided a business update.

May 18, 2023
·
12 min read
ImmunoForge Expands Drug Development Licensing Agreement with Duke University

ImmunoForge has announced on the 18th that it has expanded its license rights with Duke University to enhance joint research and drug development opportunities in relation to the elastin-like polypeptide platform technology.

May 18, 2023
·
3 min read
Pharm Country

JDRF Encourages Everyone Living with Diabetes to be Proactive about Eye Health in Recognition of Healthy Vision Month

In recognition of Healthy Vision Month, JDRF, the leading global type 1 diabetes research and advocacy organization, encourages everyone living with diabetes to be proactive about their eye health.

May 18, 2023
·
3 min read
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ) today announced positive top line pilot study results for the StemSpine® procedure using AlloStem™ to treat chronic lower back pain.

May 18, 2023
·
3 min read
Genetown

Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons

Alltrna today announces the presentation of the first proof-of-concept data at multiple scientific forums this month.

May 18, 2023
·
5 min read